Compare FCN & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCN | INDV |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.7B |
| IPO Year | 1996 | 2014 |
| Metric | FCN | INDV |
|---|---|---|
| Price | $151.70 | $34.94 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $165.00 | N/A |
| AVG Volume (30 Days) | 340.9K | ★ 1.9M |
| Earning Date | 04-30-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.51 | ★ 8100.00 |
| EPS | ★ 3.89 | 1.67 |
| Revenue | ★ $3,788,857,000.00 | $1,239,000,000.00 |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | $39.47 | ★ $20.90 |
| Revenue Growth | 2.44 | ★ 4.29 |
| 52 Week Low | $137.65 | $22.22 |
| 52 Week High | $189.30 | $42.81 |
| Indicator | FCN | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 32.20 |
| Support Level | $153.47 | $32.06 |
| Resistance Level | $157.23 | $35.54 |
| Average True Range (ATR) | 3.56 | 1.05 |
| MACD | 0.04 | -0.22 |
| Stochastic Oscillator | 55.15 | 10.23 |
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).